Business Description
![Zymeworks Inc Zymeworks Inc logo](https://static.gurufocus.com/logos/0C0000B8PX.png?14)
Zymeworks Inc
NAICS : 325412
SIC : 2836
ISIN : CA98985W1023
Share Class Description:
ZYME: Registered ShsDescription
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 13.68 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.19 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.16 | |||||
Beneish M-Score | -2.06 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.6 | |||||
3-Year EBITDA Growth Rate | 20.7 | |||||
3-Year EPS without NRI Growth Rate | 22.1 | |||||
3-Year FCF Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | -9.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 15.66 | |||||
Future 3-5Y Total Revenue Growth Rate | 24.59 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 79.92 | |||||
9-Day RSI | 75.71 | |||||
14-Day RSI | 71.8 | |||||
6-1 Month Momentum % | -19.23 | |||||
12-1 Month Momentum % | 11.85 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.92 | |||||
Quick Ratio | 6.92 | |||||
Cash Ratio | 6.07 | |||||
Days Sales Outstanding | 337.68 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.1 | |||||
Shareholder Yield % | -3.09 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -294.33 | |||||
Net Margin % | -249.63 | |||||
FCF Margin % | -152.83 | |||||
ROE % | -28 | |||||
ROA % | -21.77 | |||||
ROIC % | -75.48 | |||||
ROC (Joel Greenblatt) % | -318.48 | |||||
ROCE % | -29.15 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.99 | |||||
PB Ratio | 1.73 | |||||
Price-to-Tangible-Book | 1.9 | |||||
EV-to-EBIT | -2.9 | |||||
EV-to-EBITDA | -3.27 | |||||
EV-to-Revenue | 8.54 | |||||
EV-to-Forward-Revenue | 7.83 | |||||
EV-to-FCF | -5.59 | |||||
Price-to-Net-Current-Asset-Value | 2.74 | |||||
Price-to-Net-Cash | 3.32 | |||||
Earnings Yield (Greenblatt) % | -34.48 | |||||
FCF Yield % | -10.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZYME
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zymeworks Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 50.464 | ||
EPS (TTM) ($) | -1.78 | ||
Beta | 1.38 | ||
Volatility % | 47.61 | ||
14-Day RSI | 71.8 | ||
14-Day ATR ($) | 0.41364 | ||
20-Day SMA ($) | 9.532 | ||
12-1 Month Momentum % | 11.85 | ||
52-Week Range ($) | 6.015 - 13.14 | ||
Shares Outstanding (Mil) | 70.7 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Zymeworks Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Zymeworks Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Zymeworks Inc Frequently Asked Questions
What is Zymeworks Inc(ZYME)'s stock price today?
The current price of ZYME is $10.74. The 52 week high of ZYME is $13.14 and 52 week low is $6.02.
When is next earnings date of Zymeworks Inc(ZYME)?
The next earnings date of Zymeworks Inc(ZYME) is 2024-08-01.
Does Zymeworks Inc(ZYME) pay dividends? If so, how much?
Zymeworks Inc(ZYME) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |